Co-Diagnostics, Inc. Overview
CODX market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
CODX price chart · 1M
- O
- 0.263600
- H
- 0.289300
- L
- 0.263600
- C
- 0.283100
- Vol
- 25,585.00
Daily history from Jul 12, 2017
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $0.26
- Previous Close
- $0.33
- Day High
- $0.29
- Day Low
- $0.26
- 52 Week High
- $13.51
- 52 Week Low
- $0.25
- 7 Day Return
- -25.42%
- 30 Day Return
- -77.35%
- 90 Day Return
- -80.87%
- 1 Year Return
- -97.60%
- Daily Notional Volume
- $7.2K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$35.25 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.33 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -6,523.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.25 – $13.54 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.7M · P/B 0.50 · P/S 3.73.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Co-Diagnostics Q3 EPS $(1.01) Beats $(1.25) Estimate, Sales $282.881K Beat $169.000K EstimateBenzinga ·
8-K filing — Co-Diagnostics, Inc. (CODX)SEC EDGAR ·
Co-Diagnostics Joint Venture CoSara Submits Tuberculosis Test for Regulatory Clearance in IndiaFiscal.ai ·
8-K/A filing — Co-Diagnostics, Inc. (CODX)SEC EDGAR ·